Q2 2024 EPS Estimates for Hims & Hers Health, Inc. Lifted by Analyst (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Seaport Res Ptn boosted their Q2 2024 earnings per share (EPS) estimates for Hims & Hers Health in a research report issued to clients and investors on Monday, May 6th. Seaport Res Ptn analyst A. Kessler now forecasts that the company will post earnings per share of $0.05 for the quarter, up from their previous forecast of $0.02. Seaport Res Ptn currently has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2024 earnings at $0.19 EPS and FY2025 earnings at $0.37 EPS.

Several other equities analysts have also recently commented on HIMS. SVB Leerink initiated coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 price target on the stock. Guggenheim raised their price target on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Truist Financial boosted their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Piper Sandler raised their price objective on shares of Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Citigroup boosted their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average target price of $15.08.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $12.92 on Wednesday. The company has a market capitalization of $2.77 billion, a PE ratio of -117.36 and a beta of 0.97. The company’s 50 day moving average price is $13.99 and its 200 day moving average price is $10.41. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The company had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.05) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Graham Capital Management L.P. grew its holdings in shares of Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after purchasing an additional 96,277 shares during the last quarter. Swiss National Bank increased its holdings in shares of Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after buying an additional 26,100 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after acquiring an additional 428,671 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after acquiring an additional 58,288 shares in the last quarter. Finally, Must Asset Management Inc. bought a new stake in Hims & Hers Health during the 3rd quarter worth approximately $1,596,000. 63.52% of the stock is owned by institutional investors.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 22,839 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17. Following the transaction, the insider now owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the completion of the sale, the chief executive officer now owns 51,653 shares in the company, valued at approximately $494,835.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Soleil Boughton sold 22,839 shares of Hims & Hers Health stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $10.03, for a total value of $229,075.17. Following the sale, the insider now directly owns 154,345 shares in the company, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. Insiders sold a total of 723,602 shares of company stock worth $9,607,432 in the last 90 days. 31.63% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.